Skip to main content

Market Overview

COV To Enjoy Significant Margin Expansion

Share:

Analyst Matthew J Dodds of Citi Investment Research & Analysis maintains his "buy" rating on Covidien Ltd (NYSE: COV), while raising his estimates for the company. The target price for COV has been raised from $53 to $56.

According to Citi Investment Research & Analysis, Covidien’s gross margins and operating margins are expected to increase significantly in the forthcoming quarters, driven by the strength in the general surgery market and acquisitions and divestitures. Despite the weak macroeconomic trends, the general surgery market remains robust, the analyst said.

The market under-appreciate the positive effects of Covidien’s recent acquisitions and divestitures, the analyst added. Citi Investment Research & Analysis has raised its EPS estimates for 2010 and 2011 from $3.28 to $3.29 and from $3.60 to $3.70, respectively.

 

Related Articles (COV)

View Comments and Join the Discussion!

Posted-In: Citi Investment Research & Analysis Matthew J DoddsAnalyst Color Price Target Analyst Ratings

Latest Ratings

StockFirmActionPT
SEDGB of A SecuritiesMaintains411.0
PTLOPiper SandlerMaintains28.0
AOUTLake StreetMaintains26.0
RAPTPiper SandlerMaintains52.0
OCXLake StreetMaintains6.0
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
SPAC
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com